2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasm Metastasis
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Camurati-Engelmann Syndrome
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Melanoma
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
91
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
25
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
bintrafusp alfa protein, human
×
Clear all
NCT04878250
2021-05-07
PEBBLE
Queen Mary University of London
Phase 2
Unknown
49 enrolled